Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 4, 2003, Pages 577-585

  Coffin, B ^a,e   Farmachidi, J P ^a   Rueegg, P ^b   Bastie, A ^c   Bouhassira, D ^d,e  

^a HÔPITAL LOUIS MOURIER   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

^d AP HP Hop Ambroise Pare   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 4 AGONIST; TEGASEROD; INDOLE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ARTICLE; CHICKENPOX; CONTROLLED STUDY; DRUG SENSITIVITY; ELECTROPHYSIOLOGY; FEMALE; FLEXOR REFLEX; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; IRRITABLE COLON; NOCICEPTION; NORMAL HUMAN; PRIORITY JOURNAL; RECTUM MOTILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; PAIN; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PRESSURE; RANDOMIZED CONTROLLED TRIAL; RECTUM; REFLEX; SENSITIVITY AND SPECIFICITY;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MIDDLE AGED; PAIN; PRESSURE; RECTUM; REFLEX; SENSITIVITY AND SPECIFICITY; SENSORY THRESHOLDS; SEROTONIN AGONISTS;

EID: 0037441307     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01449.x     Document Type: Article

References (40)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Ervine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
2. Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122: 2032-48.
3. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
4. Willer JC. Comparative study of perceived pain and nociceptive flexion reflex in man. Pain 1977; 3: 69-80.
5. Willer JC, De Broucker T, Le Bars D. Encoding of nociceptive thermal stimuli by diffuse noxious inhibitory controls in humans. J Neurophysiol 1989; 62: 1028-38.
6. Bouhassira D, Chollet R, Coffin B, et al. Inhibition of a somatic nociceptive reflex by gastric distension in humans. Gastroenterology 1994; 107: 985-92.
7. Bouhassira D, Sabate JM, Coffin B, Le Bars D, Willer JC, Jian R. Effects of rectal distensions on nociceptive flexion reflexes in humans. Am J Physiol 1998; 275: G410-7.
8. Sabate JM, Coffin B, Jian R, Le Bars D, Bouhassira D. Rectal sensitivity assessed by a reflexologic technique: further evidence for two types of mechanoreceptors. Am J Physiol Gastrointest Liver Physiol 2000; 279: G692-9.
9. Bouhassira D, Chitour D, Villaneuva L, Le Bars D. The spinal transmission of nociceptive information: modulation by the caudal medulla. Neuroscience 1995; 69: 931-8.
10. Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265: G742-51.
11. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-8.
12. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 277-89.
13. Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997; 62: 546-55.
14. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
15. Fioramonti J, Million M, Bueno L. Investigations on a 5-HT4 receptor agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and gastric emptying. Gastroenterology 1998; 114: A752-G3103 (Abstract).
16. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280: 1270-6.
17. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
18. Coelho AM, Rovira P, Fioramonti J. Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology 2000; 118: A834(Abstract).
19. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14: 221-7.
20. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
21. Novick J, Miner P, Krause R, et al. Tegaserod relieves multiple symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
22. Sun WM, Read NW, Prior A, Daly JA, Cheah SK, Grundy D. Sensory and motor responses to rectal distension vary according to rate and pattern of balloon inflation. Gastroenterology 1990; 99: 1008-15.
23. Cervero F. Sensory innervation of the viscera: peripheral basis of visceral pain. Physiol Rev 1994; 74: 95-138.
24. Lembo T, Munakata J, Mertz H, et al. Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994; 107: 1686-96.
25. Cadden SW, Morrison JF. Effects of visceral distension on the activities of neurones receiving cutaneous inputs in the rat lumbar dorsal horn: comparison with effects of remote noxious somatic stimuli. Brain Res 1991; 558: 63-74.
26. Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979; 6: 283-304.
27. De Broucker T, Cesaro P, Willer JC, Le Bars D. Diffuse noxious inhibitory controls in man. Involvement of the spinoreticular tract. Brain 1990; 113(4): 1223-34.
28. Willer JC, Roby A, Le Bars D. Psychophysical and electrophysiological approaches to the pain-relieving effects of heterotopic nociceptive stimuli. Brain 1984; 107(4): 1095-112.
29. Le Bars D, Willer JC, De Broucker T. Morphine blocks descending pain inhibitory controls in humans. Pain 1992; 48: 13-20.
30. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res 1982; 236: 329-37.
31. Kraus E, Besson JM, Le Bars D. Behavioral model for diffuse noxious inhibitory controls (DNIC): potentiation by 5-hydroxytryptophan. Brain Res 1982; 231: 461-5.
32. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
33. Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distensions. Am J Physiol 1998; 274: G584-90.
34. Beecher HK. The measurement of pain. Pharmacol Rev 1957; 9: 59-209.
35. Chapman LF, Dingman HF, Ginzberg SP. Failure of systemic analgesic agents to alter the absolute sensory threshold for the simple detection of pain. Brain 1965; 88: 1011-22.
36. Guirimand F, Dupont X, Bouhassira D, Brasseur L, Chauvin M. Nefopam strongly depresses the nociceptive flexion (R(III)) reflex in humans. Pain 1999; 80: 399-404.
37. Skljarevski V, Ramadan NM. The nociceptive flexion reflex in humans. Pain 2002; 96: 3-8.
38. Coffin B, Bouhassira D, Chollet R, et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996; 10: 919-25.
39. France CR, Suchowiecki S. A comparison of diffuse noxious inhibitory controls in men and women. Pain 1999; 81: 77-84.
40. Coffin B, Bouhassira D, Sabate JM, Barbe L, Jian R. Different mechanisms are implicated in the control of pain in patients with inflammatory bowel disease (IBD) or irritable bowel syndrome. Gastroenterology 2002; 122: M1484-A309(Abstract).